share_log

Inspira Technologies Collaborates With A Leading Israeli Medical Center For Clinical Evaluation Of INSPIRA ART Device

Inspira Technologies Collaborates With A Leading Israeli Medical Center For Clinical Evaluation Of INSPIRA ART Device

Inspira Technologies與領先的以色列醫療中心合作,對INSPIRA抗逆轉錄病毒治療設備進行臨床評估
Benzinga ·  02/08 22:08

The parties have entered a non-binding Letter of Intent

雙方簽訂了不具約束力的意向書

RA'ANANA, Israel, Feb. 8, 2024 /PRNewswire/ -- Inspira Technologies OXY BHN Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, has announced the signing of a non-binding Letter of Intent (LOI) with Shamir Medical Center (Assaf Harofeh), a renowned healthcare institution in central Israel. The Company plans to extend collaborations with further leading Israeli medical centers as part of a wider clinical deployment strategy.

以色列拉阿納納,2024年2月8日 /PRNewswire/ — Inspira Technologies OXY BHN Ltd.(納斯達克股票代碼:IINN)(納斯達克股票代碼:IINNW)(“公司” 或 “Inspira”)是生命支持技術的先驅,其願景是取代傳統機械呼吸機,宣佈與沙米爾醫療中心(阿薩夫·哈拉)簽署不具約束力的意向書(LOI)Ofeh),以色列中部一家著名的醫療機構。作爲更廣泛的臨床部署戰略的一部分,該公司計劃擴大與更多領先的以色列醫療中心的合作。

The LOI solidifies the mutual commitment of both parties to assess the integration and performance of the INSPIRA ART100 device ("Device) within Shamir Medical Center's clinical environment. This includes evaluating the device's fit with the hospital's clinical needs, efficiency in workflow, and overall impact on healthcare delivery. The hospital will procure all required disposables for operating the Devices as part of the LOI. Inspira will gain access to device operation data and user experience in a real-life clinical setting. The evaluation will be led by Dr. Eduard Ilgiyaev, Director of the Intensive Care Unit at Shamir Medical Center and a leading pioneer of critical care medicine in Israel. The progression of this LOI hinges on the AMAR (medical devices and accessories) approval by the Israeli Ministry of Health for the Device, and the subsequent formalization of a detailed definitive evaluation agreement between the parties.

意向書鞏固了雙方的共同承諾,即評估INSPIRA ART100 設備(“設備)在沙米爾醫療中心臨床環境中的集成和性能。這包括評估設備是否符合醫院的臨床需求、工作流程的效率以及對醫療服務的總體影響。作爲意向書的一部分,醫院將採購操作設備所需的所有一次性用品。Inspira將在現實臨床環境中獲得設備操作數據和用戶體驗。評估將由沙米爾醫療中心重症監護室主任、以色列重症監護醫學的領先先驅愛德華·伊爾吉亞耶夫博士領導。該意向書的進展取決於以色列衛生部對該設備的AMAR(醫療器械和配件)的批准,以及隨後雙方之間詳細的最終評估協議的正式化。

Joe Hayon, President of Inspira Technologies, stated: "With the anticipated U.S. Food and Drug Administration (FDA) approval on the horizon, I am confident that this prospective collaboration with Shamir Medical Center will enhance the efficacy of life-support care and establish a pathway for its adoption in both local and international markets."

Inspira Technologies總裁喬·海恩表示:“隨着美國食品藥品監督管理局(FDA)的批准即將到來,我相信,與沙米爾醫療中心的這種潛在合作將提高生命支持護理的功效,併爲其在本地和國際市場的採用鋪平道路。”

About Shamir Medical Center (Assaf Harofeh)

關於沙米爾醫療中心(Assaf Harofeh)

Shamir Medical Center (Assaf Harofeh), Israel's fourth-largest government hospital, is a beacon of advanced medical care, serving over 1 million residents in the central region. Known for its state-of-the-art facilities and commitment to medical innovation, the hospital is currently transforming to meet the growing population's needs. Renowned for its excellence in critical care, the Intensive Care Unit (ICU) at Shamir Medical Center is a model of innovation, particularly in Extracorporeal Membrane Oxygenation (ECMO) expertise. With a focus on patient-centered interventions, the ICU leads in awake ECMO treatment, demonstrating a dedication to advancing critical care during the COVID-19 pandemic. Overall, Shamir Medical Center remains at the forefront of medical excellence, contributing significantly to the global medical community through publications, ongoing research projects, and a commitment to pushing the boundaries of critical care.

沙米爾醫療中心(Assaf Harofeh)是以色列第四大政府醫院,是先進醫療服務的燈塔,爲中部地區的100多萬居民提供服務。該醫院以其最先進的設施和對醫療創新的承諾而聞名,目前正在進行轉型以滿足不斷增長的人口需求。沙米爾醫療中心的重症監護室(ICU)以其卓越的重症監護而聞名,是創新的典範,尤其是在體外膜氧合(ECMO)專業知識方面。重症監護病房側重於以患者爲中心的干預措施,在清醒 ECMO 治療方面處於領先地位,這表明了在 COVID-19 疫情期間致力於推進重症監護的決心。總體而言,沙米爾醫療中心仍然處於卓越醫療的最前沿,通過出版物、正在進行的研究項目以及對突破重症監護界限的承諾,爲全球醫學界做出了重大貢獻。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論